The value of serum type II collagen epitope measurement in assessing early clinical response to treatment with anti-tumour necrosis factor alpha therapy in rheumatoid arthritis

Eitemau Tebyg

• Oncostatin M in rheumatoid arthritis: a key cytokine acts synergistically with other proinflammatory cytokines to promote human cartilage loss
  gan: Fearon, U, et al.
  Cyhoeddwyd: (2005)
• Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biologic therapies
  gan: Moran, Ellen M, et al.
  Cyhoeddwyd: (2009)
• Peptostreptococcal pericarditis complicating anti-tumour necrosis factor α treatment in rheumatoid arthritis
  gan: Harney, S, et al.
  Cyhoeddwyd: (2002)
• Production of angiotensin converting enzyme by rheumatoid synovial membrane.
  gan: Veale, D, et al.
  Cyhoeddwyd: (1992)
• Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder
  gan: Balogh, Emese, et al.
  Cyhoeddwyd: (2013)